Considerations for Designing an Optimal First in Human Radiopharmaceutical Trial

Time: 11:45 am
day: Day One ESC AM


  • Evolving strategy and lessons learned from moving from lab to clinic
  • From ADC to RPT, our lessons learned about FIH study design dynamics about safety, dosimetry and PK/PD from Th227 to Ac225
  • Engaging with multidisciplinary teams: internal and external stakeholders (NM physicians, imaging and radiopharmacists, regulatory)